Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark D Vincent

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Cancer Letters|November 7, 2008
Enhancement of cytotoxicity of natural product drugs against multidrug resistant variant cell lines of human head and neck squamous cell carcinoma and breast carcinoma by tesmilifenePeter J Ferguson, Alayne R Brisson, James Koropatnick, et al.
Frontiers in Oncology|August 27, 2014
Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRASGrzegorz J Korpanty, Donna M Graham, Mark D Vincent, et al.
Cancer Gene Therapy|April 8, 2003
A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistanceRandal W Berg, Peter J Ferguson, Mark D Vincent, et al.
Gene Expression|July 4, 2007
Antisense targeting of thymidylate synthase (TS) mRNA increases TS gene transcription and TS protein: effects on human tumor cell sensitivity to TS enzyme-inhibiting drugsTracey L H Jason, Randal W Berg, Mark D Vincent, et al.
Case Reports in Oncology|October 27, 2021
Skin Deep: A Fascinating Case Report of Immunotherapy-Triggered, Treatment-Refractory Autoimmune Lichen Planus and KeratoacanthomaBeatrice T B Preti, Alec Pencz, Jeffery J M Cowger, et al.
Clinical Lung Cancer|January 30, 2020
Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Non-small-cell Lung Cancer: A Systematic Review and Meta-analysisJacques Raphael, Anupam Batra, Gabriel Boldt, et al.
DNA and Cell Biology|March 25, 2008
ODN 491, a novel antisense oligodeoxynucleotide that targets thymidylate synthase, exerts cell-specific effects in human tumor cell linesTracey L H Jason, Rene Figueredo, Peter J Ferguson, et al.
Molecular Cancer Therapeutics|July 5, 2006
Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesotheliomaJanet Flynn, Randal W Berg, Tracy Wong, et al.
Clinical Colorectal Cancer|July 31, 2016
Pretreatment Serum Folate Levels and Toxicity/Efficacy in Colorectal Cancer Patients Treated With 5-Fluorouracil and Folinic AcidMichael Yan, Cheryl Ho, Eric Winquist, et al.
Oncotarget|June 19, 2015
siRNA knockdown of mitochondrial thymidine kinase 2 (TK2) sensitizes human tumor cells to gemcitabineChristine Di Cresce, Rene Figueredo, Mateusz Rytelewski, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Cancer Letters|November 7, 2008
Enhancement of cytotoxicity of natural product drugs against multidrug resistant variant cell lines of human head and neck squamous cell carcinoma and breast carcinoma by tesmilifenePeter J Ferguson, Alayne R Brisson, James Koropatnick, et al.
Frontiers in Oncology|August 27, 2014
Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRASGrzegorz J Korpanty, Donna M Graham, Mark D Vincent, et al.
Cancer Gene Therapy|April 8, 2003
A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistanceRandal W Berg, Peter J Ferguson, Mark D Vincent, et al.
Gene Expression|July 4, 2007
Antisense targeting of thymidylate synthase (TS) mRNA increases TS gene transcription and TS protein: effects on human tumor cell sensitivity to TS enzyme-inhibiting drugsTracey L H Jason, Randal W Berg, Mark D Vincent, et al.
Case Reports in Oncology|October 27, 2021
Skin Deep: A Fascinating Case Report of Immunotherapy-Triggered, Treatment-Refractory Autoimmune Lichen Planus and KeratoacanthomaBeatrice T B Preti, Alec Pencz, Jeffery J M Cowger, et al.
Clinical Lung Cancer|January 30, 2020
Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Non-small-cell Lung Cancer: A Systematic Review and Meta-analysisJacques Raphael, Anupam Batra, Gabriel Boldt, et al.
DNA and Cell Biology|March 25, 2008
ODN 491, a novel antisense oligodeoxynucleotide that targets thymidylate synthase, exerts cell-specific effects in human tumor cell linesTracey L H Jason, Rene Figueredo, Peter J Ferguson, et al.
Molecular Cancer Therapeutics|July 5, 2006
Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesotheliomaJanet Flynn, Randal W Berg, Tracy Wong, et al.
Clinical Colorectal Cancer|July 31, 2016
Pretreatment Serum Folate Levels and Toxicity/Efficacy in Colorectal Cancer Patients Treated With 5-Fluorouracil and Folinic AcidMichael Yan, Cheryl Ho, Eric Winquist, et al.
Oncotarget|June 19, 2015
siRNA knockdown of mitochondrial thymidine kinase 2 (TK2) sensitizes human tumor cells to gemcitabineChristine Di Cresce, Rene Figueredo, Mateusz Rytelewski, et al.
Pageof 4